The Future of Medical Cannabis Catherine Jacobson, PhD Director, Clinical Research
The Current System Fails Patients
The Current System Fails Patients State-based Medical FDA and DEA approved Cannabis Regulations pharmaceutical products Safety & Reliability of Accessibility Products ISSUES Insurance Coverage/Cost Appropriate Medical Supervision
Expanding Access Patients with epilepsy (3 million in the US) Accessing cannabis-derived products Not accessing from medical cannabis-derived products
Clinical Data Safe Dose and Titration Schedule Basic Safety Profjle in Their Patient Population Side Effects Profjle Adverse Events Drug-drug Interactions Expected Outcomes
Medical Preparations Meet GMP Standards to Ensure Safety Chemically Defjned Reliable and Reproducible
Current Spectrum of Regulations Global Access Legal / Essentially Legal Illegal But Often Unenforced Legal (Medical Only) Illegal Decriminalized No Information
Tilray—Federally Licensed in Canada GMP-grade Cannabis GMP-grade Cannabis-derived Extracts Clinical T rial-grade
The Path Forward—Clinical Research Phase 2/3 T rial in partnership with the University of Sydney, Australia for chemotherapy-induced nausea and vomiting Phase 2/3 T rial in partnership with the Ontario Brain Institute, Canada for adult refractory epilepsy Open-label trials provide immediate patient access for specifjc indications Database: dose, side effects, indications, adverse events
Thank Y ou Catherine Jacobson, PhD Director, Clinical Research
Recommend
More recommend
